ONCY
Oncolytics Biotech Inc
0.6412$
-4.0%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +59.3% | -46.1% | +23.0% | -18.1% | +32.2% | +74.7% | +33.6% | -18.6% | +4.0% | -48.0% | -48.5% | |
| – | +61.5% | -46.4% | +23.4% | -18.9% | +31.0% | +78.2% | +33.1% | -20.5% | +7.0% | -50.6% | -50.2% | |
| – | +69.7% | -49.9% | -1.6% | +15.7% | +3.3% | +120.7% | +32.2% | -71.7% | +199.3% | -54.3% | -55.2% | |
| – | +61.1% | -45.8% | -16.2% | +15.7% | +3.3% | +120.7% | +32.2% | -22.1% | +8.6% | -54.3% | -55.2% | |
| – | +77.3% | -84.0% | +8,731.4% | -98.9% | +3,905.4% | -95.7% | +865.9% | -39.8% | -97.1% | +353.3% | +1,056.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -61.6% | +84.5% | +4.2% | +23.8% | +76.3% | -16.3% | +60.3% | -33.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -19.7% | +50.2% | +142.5% | -12.1% | +128.0% | -51.5% | +2.0% | +10.7% | +3.9% | +26.2% | +9.9% | |
| – | -19.7% | +50.2% | +28.5% | -46.2% | +357.2% | -78.9% | -0.7% | +46.7% | +7.4% | +57.8% | +25.2% | |
| – | – | – | – | -100.0% | – | -26.8% | +18.1% | -26.5% | -38.4% | +108.3% | -4.4% | |
| – | -19.7% | +50.2% | -9.5% | -50.4% | -99.8% | +56,782.8% | -67.1% | +279.1% | -52.0% | +0.5% | +342.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +78.6% | -56.7% | -22.5% | -25.2% | -101.7% | – | +45.8% | -26.6% | +4.0% | -78.3% | -187.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +28.2% | +6.5% | +10.4% | +14.9% | +38.2% | +82.2% | +32.7% | +8.4% | +16.5% | +13.1% | +25.3% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.